US LNG exports surge but will buyers in China turn up?
Investing.com -- Galenica reported 6% top line growth for 2Q25, with sales reaching CHF681 million, slightly above consensus expectations of CHF679 million. The Swiss healthcare company posted first-half adjusted EBIT of CHF110 million with a margin of 5.5%, while adjusted net income came in at CHF91 million, exceeding analyst consensus of CHF87 million.
In the Products & Care segment, 2Q25 sales grew 3% to CHF295 million, below consensus estimates of CHF300 million. Growth in Local Pharmacies helped offset organic headwinds in the Products & Brands division. The segment recorded first-half adjusted EBIT of CHF80 million with a 9.2% margin.
The Logistics & IT segment showed stronger performance with 2Q25 revenues of CHF564 million, representing approximately 7% growth and surpassing consensus expectations of CHF547 million. This growth was driven by wholesale services to physicians (8%) and pharmacies (7%).
First-half adjusted EBIT for the segment reached CHF32 million with a 1.9% margin, benefiting from a CHF5 million positive one-off related to a new legal assessment of the ComCo sanction involving HCI Solutions and Markant.
Following these results, Galenica raised its full-year 2025 EBIT growth guidance to 7%-9%, up from the previous 4%-6%, primarily due to the one-off benefit. The company maintained its FY25 group sales growth target of 3-5%. The guidance does not include the previously announced acquisition of a diagnostic lab service provider, as this transaction has not yet been completed.
Current market consensus expects FY25 revenue growth of 4.5% and adjusted EBIT growth of 5.4%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.